Repeat bronchoalveolar lavage in idiopathic pulmonary fibrosis: proceed with caution?
- PMID: 34045285
- DOI: 10.1183/13993003.00691-2021
Repeat bronchoalveolar lavage in idiopathic pulmonary fibrosis: proceed with caution?
Conflict of interest statement
Conflict of interest: M.G. Jones reports grants from Boehringer Ingelheim, outside the submitted work. Conflict of interest: M. Kolb has received grants and personal fees from Roche, Boehringer Ingelheim, GSK, Gilead, Prometic (now Liminal Biosciences) and Pieris; grants from Avalyn; and personal fees from AstraZeneca, Novartis, Cipla, Bluefin Biomedicine, Algernon and Medscape.
Comment on
-
Target inhibition of galectin-3 by inhaled TD139 in patients with idiopathic pulmonary fibrosis.Eur Respir J. 2021 May 27;57(5):2002559. doi: 10.1183/13993003.02559-2020. Print 2021 May. Eur Respir J. 2021. PMID: 33214209 Free PMC article. Clinical Trial.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources